Enfumafungin Derivative MK-3118 Shows IncreasedIn VitroPotency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates

Abstract

ABSTRACTMK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated thein vitroactivity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in theFKSgene(s) ofCandidaspp. andAspergillusspp. MK-3118 demonstrated enhanced efficacy for mostC. albicansandC. glabrataER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).